80 likes | 181 Views
Plasma Lipoprotein and Apo Levels at Baseline and Lipoprotein Levels on Treatment in Pravastatin-Treated Subjects in PROSPER. PROSPER Study C.J. Packard et al, Circulation 2005; 112: 3058-3065. Relation between baseline lipoprotein levels and incidence of the primary end point.
E N D
Plasma Lipoprotein and Apo Levels at Baseline and Lipoprotein Levels on Treatment in Pravastatin-Treated Subjects in PROSPER PROSPER Study C.J. Packard et al, Circulation 2005; 112: 3058-3065
Relation between baseline lipoprotein levels and incidence of the primary end point PROSPER Study C.J. Packard et al, Circulation 2005; 112: 3058-3065
RR of primary end point by quintile of baseline LDLc and baseline HDLc PROSPER Study C.J. Packard et al, Circulation 2005; 112: 3058-3065
Pravastatin Treatment Effect by Quintile (Q) of Baseline Lipoprotein Levels PROSPER Study C.J. Packard et al, Circulation 2005; 112: 3058-3065
Relation between on-treatment lipoprotein levels and risk of the primary end point PROSPER Study C.J. Packard et al, Circulation 2005; 112: 3058-3065
Lipoprotein Variables in Models of Outcome in the Whole PROSPER Cohort - Part I PROSPER Study C.J. Packard et al, Circulation 2005; 112: 3058-3065
Lipoprotein Variables in Models of Outcome in the Whole PROSPER Cohort - Part II PROSPER Study C.J. Packard et al, Circulation 2005; 112: 3058-3065
Representative Multivariate Model of Treatment Effect on Lipid Levels* PROSPER Study C.J. Packard et al, Circulation 2005; 112: 3058-3065